Traditional MedicareCoverageHigh impact
Off-Label Use of Intravenous Immune Globulin (IVIG)
Medicare/CMS - LCD·Allergy & Immunology, Rheumatology, Neurology +5 more·Local Coverage Determination
Effective date
Apr 1, 2026
We identified it
Jul 28, 2026
Summary
Wellpoint Federal (MAC Part A/B) has issued a new Local Coverage Determination (L39314) effective April 1, 2026, establishing coverage criteria and payment rules for off-label uses of Intravenous Immune Globulin (IVIG). This policy defines which off-label IVIG indications are covered under Medicare, which likely affects prior authorization requirements, medical necessity documentation, and billing for IVIG administration across multiple specialties.
Action Required
By March 31, 2026: Billing team must review the complete LCD L39314 policy text from the CMS coverage database to identify specific HCPCS codes for IVIG products (typically J-codes) and any new prior authorization or documentation requirements. Update billing software, encounter forms, and provider education materials to reflect coverage criteria for off-label IVIG use. Providers must document medical necessity according to the policy's clinical criteria before billing. Communicate policy requirements to all clinical staff who order or administer IVIG. Claims submitted without meeting the policy's coverage criteria or missing required documentation will be denied by Wellpoint Federal.